Key Highlights

  • 9.37% is the indicated pre-market gain for Savara Inc. (NASDAQ:SVRA) on November 18, 2026, lifting the price to USD 4.90 from a calculated prior close of USD 4.48, a calculated move of USD 0.42.
  • 22 is the day of November 2026 set as the FDA PDUFA goal date for molgramostim, after a three-month extension that followed a major amendment to the application under priority review.
  • 130 million is the USD balance of cash, cash equivalents and short-term investments at September 30, 2026, against a third-quarter net loss of USD 43 million, up about 45% year over year.
  • 150 million is the USD contingent financing, made up of USD 75 million from RTW Investments and up to USD 75 million of Hercules term loans, available if approval comes by March 31, 2027.

What Moved Savara Inc. (NASDAQ:SVRA) in Pre-Market Trading on November 18, 2026 (+USD 0.42, +9.37%)

The indicated pre-market price for Savara Inc. (NASDAQ:SVRA) is USD 4.90 on November 18, 2026, a pre-market move of +9.37%. The calculated prior close, the November 17, 2026 regular-session close, is USD 4.48 (USD 4.90 divided by 1.0937), and the calculated USD move is +USD 0.42. Pre-market volume, shares outstanding and a corroborated market Capitalization were not found in published coverage, so the move is not set against a market value.

The Rationale: No Same-Day Release, With the FDA Decision Date Approaching for Savara Inc. (NASDAQ:SVRA)

No company release dated November 18, 2026 was identified in published coverage. The nearest scheduled event is the Prescription Drug User Fee Act goal date of November 22, 2026 for molgramostim, after the FDA extended its review by three months following a major amendment. As general context, shares of clinical-stage and pre-commercial drugmakers often move in the days before a regulatory decision as investors position for either outcome. Savara has also been validated for review in the European Union and the United Kingdom under an accelerated 150-day pathway.

Valuation, Liquidity and Risks for Savara Inc. (NASDAQ:SVRA)

Third-quarter 2026 net loss was USD 43 million, with Research and Development expense of USD 25 million, up 21%, and general and administrative expense of USD 19 million, up 93%, largely on commercial team growth and stock-based compensation. Total operating expenses were USD 44 million, up 44%, and operating cash burn was USD 105 million over nine months. Cash and short-term investments of USD 130 million compare with that pace of use, and the Hercules Facility carries minimum cash and trailing net product Revenue covenants with dates extended to April 1, 2027 and September 30, 2027. The key risk is regulatory: a delay or a negative decision would affect access to the USD 150 million of contingent financing.

Where Things Stand

Savara Inc. (NASDAQ:SVRA) is indicated up 9.37% in pre-market trading on November 18, 2026, at USD 4.90, a calculated USD 0.42 above a prior close of USD 4.48. No same-day company release was identified in published coverage. The most relevant dated event is the November 22, 2026 FDA goal date for molgramostim. The latest reported quarter showed a net loss of USD 43 million, operating expenses of USD 44 million and cash and short-term investments of USD 130 million. Contingent financing of up to USD 150 million depends on approval by March 31, 2027. Pre-market moves can reverse at the 9:30 a.m. ET open, and this is not Investment advice.